Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)

Trials by Status

recruiting125%
not_yet_recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_4

Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma

NCT07508098
not_yet_recruitingnot_applicable

Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma

NCT06780644
recruitingnot_applicable

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

NCT06516419
completedphase_2

Solar Lentigines Treatment With the Triple Combination Cream

NCT00975312

Clinical Trials (4)

Showing 4 of 4 trials
NCT07508098Phase 4

Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma

Completed
NCT06780644Not Applicable

Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma

Not Yet Recruiting
NCT06516419Not Applicable

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Recruiting
NCT00975312Phase 2

Solar Lentigines Treatment With the Triple Combination Cream

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4